Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrahypofractionation of localized prostate cancer-an updated statement of the prostate cancer working group of the German Society of Radiation Oncology (DEGRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

Biomarkers in prostate cancer: current status and future directions in radiotherapy-statement from the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2025
Same author

The risk of second malignancies following prostate cancer radiotherapy in the era of conformal radiotherapy: a statement of the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2024
Same author

Dynamic phenotypic shifts and M2 receptor downregulation in bladder smooth muscle cells induced by mirabegron.

Frontiers in pharmacology·2024
Same author

Prostate cancer and elective nodal radiation therapy for cN0 and pN0-a never ending story? : Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2024
Same author

[Urinary diversion for acute epididymitis : Transurethral or suprapubic catheter?]

Urologie (Heidelberg, Germany)·2022

Related Experiment Video

Updated: Mar 25, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K

[Localized intermediate- to high-risk prostate cancer].

S Tritschler1, U Ganswindt2, C G Stief3

  • 1Urologische Klinik und Poliklinik, Klinikum Großhadern der LMU, Marchioninistr. 15, 81377, München, Deutschland. stefan.tritschler@med.uni-munchen.de.

Der Urologe. Ausg. A
|February 14, 2016
PubMed
Summary

Radical prostatectomy (RP) offers better survival outcomes than external beam radiation therapy (EBRT) for intermediate- and high-risk prostate cancer, particularly in younger patients. Both treatments have low mortality but distinct side effects like incontinence or rectal issues.

Keywords:
External beam radiation therapyMorbidityMortalityRadical prostatectomyRadiotherapy

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

1.9K

Related Experiment Videos

Last Updated: Mar 25, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

1.9K

Area of Science:

  • Urology
  • Oncology
  • Radiation Oncology

Background:

  • Radical prostatectomy (RP) and external beam radiation therapy (EBRT) are standard treatments for intermediate- and high-risk prostate cancer.
  • RP survival benefits are established by randomized trials, while EBRT benefits and direct RP vs. EBRT comparisons rely on retrospective analyses with inherent limitations.

Purpose of the Study:

  • To compare the efficacy and outcomes of radical prostatectomy (RP) versus external beam radiation therapy (EBRT) for prostate cancer treatment.
  • To evaluate survival rates and complications associated with both RP and EBRT in prostate cancer patients.

Main Methods:

  • Review and synthesis of existing retrospective studies comparing radical prostatectomy (RP) and external beam radiation therapy (EBRT).
  • Analysis of data regarding overall survival, cancer-specific survival, and post-interventional morbidity.

Main Results:

  • Most comparative studies indicate that RP is superior to EBRT regarding overall and cancer-specific survival.
  • RP appears more beneficial for young patients with high-grade prostate cancer, potentially reducing the need for subsequent radiotherapy.
  • Both RP and EBRT exhibit low mortality rates, but RP complications include urinary incontinence and erectile dysfunction, while EBRT can cause rectal sequelae, erectile dysfunction, and urinary symptoms.

Conclusions:

  • Radical prostatectomy (RP) demonstrates a survival advantage over external beam radiation therapy (EBRT) for intermediate- and high-risk prostate cancer.
  • RP may be the preferred treatment for younger, high-grade prostate cancer patients due to potentially better long-term outcomes and reduced need for salvage therapy.
  • Understanding the distinct morbidity profiles of RP and EBRT is crucial for patient counseling and treatment selection.